Saffron: Mood, Sleep, Eye Health and Supplement Evidence

What is saffron?

Saffron is the dried stigma, the thread-like part inside the flower, of Crocus sativus. Supplements use concentrated extracts of the stigma.

People take saffron for low mood, anxiety and sleep, with smaller lines of research into attention-deficit/hyperactivity disorder (ADHD), medication-related sexual problems and age-related macular degeneration (AMD). What trials suggest: small trials, many from Iran, found that 28 to 30 mg a day improved mild to moderate depression scores compared with placebo, and some found it similar to common antidepressants. Reviews also found signs that negative studies went unpublished, so the true effect is probably smaller.

Historical use and modern supplements

Saffron has a history as a food ingredient, coloring and remedy. A University of Cambridge archival account^[1] describes English household uses and Hannah Woolley’s 1670 inclusion of the spice in a preparation called “Melancholy Water.” The 2005 depression trial^[2] also identifies traditional Persian use for mood as a reason for studying saffron.

What people take saffron for

Trials enrolled people with mild to moderate symptoms, not severe depression or suicidal thoughts.

When to ask a doctor before taking saffron

• You take an antidepressant or other mood medicine. Involve the prescriber before adding saffron; the add-on trial used clinical supervision.
• You have bipolar disorder. Discuss it with your psychiatrist. A small depression trial^[3] excluded bipolar disorder but still recorded hypomania—episodes of unusually elevated or irritable mood and increased energy—in 2 of 15 saffron participants and 1 of 15 taking imipramine; it cannot establish the risk in bipolar disorder.
• You take blood thinners. Ask the prescriber or pharmacist before adding saffron; combination safety has not been established in the research assessed here.

Selected extracts and forms

The 88.5 mg product is not a stronger version of the 28–30 mg stigma extracts; it is a different extract studied for a different purpose.

What to pay attention to on the label

The label should identify Crocus sativus stigma and give extract milligrams for the full serving.

Which number on the label is the amount?

One gummy product lists 28 mg of affron per two-gummy serving, along with vitamin D and 3 g of added sugar.

Misleading labels

Cheap saffron powder

Because saffron is so expensive, powders are often mixed with safflower or turmeric. A low price for a large amount is a warning sign.

A mood claim attached to a named extract

A “promotes a positive mood” or “clinically studied” line may point to a trial using 28 mg of affron in adults with low mood. That trial tested the branded extract, not any saffron powder or another extract with the same milligram amount.

Confusing servings and items per serving

Some manufacturers put 180 capsules on the front, and the back says 3 capsules per serving and 60 servings. The amount on the Supplement Facts panel is for the whole 3-capsule serving.

Appetite-control claims from another extract

An “appetite control” claim refers to a different extract and its own research, which this article does not assess. It should not be treated as a finding from the mood or sleep studies discussed here.

Common Myths about Saffron

Is saffron as good as an antidepressant?

Not proven. Small six-week trials found no significant difference from fluoxetine or imipramine, but they were not designed to establish that the treatments are equally effective. The direct comparisons are described below.

Is more saffron better?

No trial shows that. The mood trials clustered at 28 to 30 mg, and 22 mg did not work in the one trial that tested it.

Drawbacks and side effects

The 2026 safety review^[5] combined 102 trials and a case report. It gives conflicting totals for the saffron-treated participants used to calculate side-effect rates: 2,520 in one passage and 1,479 in another. That prevents a reliable single percentage from being drawn from the review.

The kidney and liver question remains unsettled. The review recommends considering monitoring, especially with higher doses or longer use; it does not establish that typical mood-study amounts are harmless to those organs.

Pregnancy

Supplement safety in pregnancy has not been established in the research assessed here. Do not take saffron supplements if you are pregnant. Culinary use is a different exposure from concentrated capsules.

The science behind saffron

The evidence shows promising small trials for mood, conflicting results between doctor and self ratings, and signs of publication bias.

Depression and low mood

There is no official daily amount. A 2005 placebo-controlled trial^[2] enrolled 40 adults with mild to moderate depression. They took 30 mg of saffron stigma extract or a placebo for 6 weeks; scores on the Hamilton depression scale, a doctor-rated questionnaire, improved more with saffron. A 2019 review of 23 trials found a large benefit over placebo but also signs of publication bias, meaning negative studies were likely never published. Most used 30 mg a day, but the review mixed stigma, petal, crocin and powder preparations; many trials were done in Iran. The authors reported no funding specifically for writing that review; separately, several disclosed relationships with pharmaceutical, food, or supplement companies. An earlier 2013 review also had commercial ties: two authors advised a saffron seller.

A separate six-week trial in 40 adults compared 30 mg of stigma extract with fluoxetine 20 mg. Results were similar, but a small comparison does not establish that saffron can replace an antidepressant. In the four-week affron trial, 128 adults had low mood without diagnosed depression; 28 mg improved mood scores, while 22 mg did not.

The broader low-mood research includes a clear miss. An eight-week Safr’Inside trial^[4] tested 30 mg/day in adults with subclinical mood symptoms and found no advantage on its primary total mood-disturbance score. A depression subscale was more favorable, at the threshold of statistical significance. The manufacturer funded the trial, and several authors were employees.

A 2026 trial in 86 women aged 50–70^[6] tested affron 28 mg/day for 12 weeks. Self-rated depression symptoms improved more than with placebo. Sleep disturbance, self-rated appearance and estimated skin age did not differ. The manufacturer funded and supplied the trial and helped with its initial design.

Another 2026 trial^[7] randomized 56 adults with low mood to UO SAF 02 at 30 mg/day or placebo for eight weeks. It reported better self-rated mood than placebo at eight weeks. The sponsor funded the study, and authors disclosed company employment and a related patent. That result needs independent replication.

Doctor ratings versus self ratings

In a 2019 eight-week trial that enrolled 160 adults, 139 provided usable data. Among those adding 28 mg of affron to antidepressants, doctors’ depression ratings fell 41 percent with saffron and 21 percent with placebo, while participants’ own ratings did not differ. A 2026 review of 34 trials found the opposite pattern: self-ratings of depression and anxiety improved, while doctor ratings did not. The reason for the disagreement is not known. Anxiety findings also depend on the scale: the 2019 review found a favorable pooled result with publication bias, while the 2026 review found improvement on the self-rated Beck anxiety scale but not the clinician-rated Hamilton scale.

Can saffron improve sleep?

Small trials suggest a benefit for some reported sleep problems. In Lopresti's placebo-controlled study^[8], 63 adults with poor sleep were randomized to 14 mg affron twice daily or placebo for 28 days; 55 contributed data. Insomnia-severity ratings, how restorative sleep felt and diary ratings of sleep quality favored saffron. The measurements were self-reported, so this trial does not tell us how much longer participants actually slept.

A second trial^[9] randomized 66 adults with mild to moderate sleep difficulties to a different extract, Saffr’activ, at 15.5 mg/day or placebo for six weeks. Fifty-nine were included in the main analyses. This study used wrist activity monitors as well as questionnaires.

The clearest monitor finding was more time in bed with saffron. Measured total sleep time and sleep efficiency—the proportion of time in bed spent asleep—did not show the same benefit. The questionnaire's sleep-duration item improved compared with placebo. Several other questionnaire scores improved within the saffron group, but that alone does not establish an advantage over placebo.

The second study therefore adds some support while narrowing the claim: feeling that sleep improved and spending longer in bed were better supported than sleeping longer on the monitor. The studies used different extracts and amounts, and neither compared saffron with an established insomnia treatment. A smaller milligram number on a different extract cannot be ranked as a better dose from these separate trials.

ADHD

There are randomized studies as well as the nonrandomized comparison often discussed online. A 2019 pilot^[10] assigned 54 children and teenagers to saffron or methylphenidate for six weeks; 50 completed it. Saffron amounts were 20–30 mg/day depending on weight. Parent and teacher symptom ratings did not differ significantly between groups.

That result is interesting, but a small trial without a placebo group cannot establish that the treatments are equally effective. It cannot distinguish all treatment effects from expectation, repeated assessment or changes over time. It also provides little information about long-term symptom control or safety.

An October 2026 trial^[11] asked a different question: whether adding saffron to methylphenidate helps. The full report describes 54 children randomized and 43 completing six weeks. Parent ratings of total symptoms and inattention improved more with the combination. Objective attention and working-memory results did not show a significant advantage over the medication-only group.

Families knew whether saffron was being added because there was no placebo supplement. That matters particularly for parent ratings. These studies justify further research, but do not establish saffron as a replacement for ADHD medication or a routine addition to a child's treatment.

Can saffron help sexual side effects of antidepressants?

Two small trials studied sexual problems in people whose depression was stable on fluoxetine. They tested saffron alongside that medicine.

In the trial in men^[12], 36 participants were randomized to 15 mg saffron twice daily or placebo for four weeks, and 30 completed treatment. Erectile function and satisfaction with intercourse improved more with saffron. Sexual desire, orgasmic function and overall satisfaction did not significantly differ.

The trial in women^[13] enrolled 38 participants, with 34 completing and providing follow-up measurements. At 30 mg/day for four weeks, saffron improved ratings of arousal, lubrication and pain compared with placebo. Desire, orgasm and satisfaction did not show a clear benefit. Tehran University supported the study, a company donated the product, and the authors declared no competing financial interests.

These findings concern particular aspects of sexual function after one antidepressant. They offer a more specific possibility than a broad “libido booster” claim. The short studies do not establish lasting benefit or the same effect with other medicines. Medication-related sexual symptoms are worth discussing with the prescriber, who can consider the supplement evidence alongside other treatment options.

Can saffron help age-related macular degeneration?

Small trials suggest an effect on the retina’s electrical response to light. Evidence for a noticeable or lasting improvement in sight is less consistent.

An early crossover trial^[14] assigned 25 people with early AMD to saffron 20 mg/day or placebo for three months, then switched treatments. Saffron improved a focal electroretinogram, a test of retinal electrical activity. A later crossover trial in 100 adults^[15] with mild to moderate AMD used the same daily amount for three months per treatment. Visual acuity improved by an average of 0.69 letters compared with placebo—less than one letter on the eye chart. People already taking an AREDS vitamin-and-mineral formula for AMD continued it.

Longer follow-up gives a mixed picture. An uncontrolled Italian study of 29 patients^[16] taking Zaffit 20 mg/day found improvements in electrical responses and visual acuity that remained stable through follow-up of up to 15 months. The supplier provided the capsules and support. Without an untreated comparison, the study cannot establish how much of the change came from saffron.

The 12-month extension of the 100-person crossover trial^[17] followed 93 of the original participants on 20 mg/day. It was the same cohort, now without a placebo comparison. Electrical-response density improved by 8.7%, but visual acuity declined by about 1.6 letters and retinal sensitivity to light also declined. Eighty participants contributed to the final visual analyses after losses to follow-up and exclusion of five whose only eligible eye progressed to neovascular, or wet, AMD, in which abnormal blood vessels grow at the back of the eye.

A separate six-month trial^[18] used 30 mg/day in people with dry or wet AMD; those with wet AMD also received bevacizumab injections. Only 40 of 60 participants completed it. Electrical-response differences favored saffron at three months but were no longer significant at six months, and the authors reported no objective improvement in visual acuity.

These studies justify further investigation of retinal function, but they do not establish prevention of vision loss or a replacement for AMD treatment. An improved electrical test and better everyday sight are different outcomes. If considering saffron for AMD, discuss the exact preparation with the ophthalmologist managing the condition.

What is still open

The main gaps are larger independent replications, sustained effects and longer-term safety. Sleep, ADHD and sexual-function studies also need to establish whether the improvements patients notice translate into durable benefits on the outcomes that matter to them.

The bottom line

Saffron has promising findings for some mood and sleep symptoms, but small studies and publication bias limit confidence. ADHD studies do not establish replacement of medication. Small fluoxetine studies suggest improvement in selected sexual symptoms, with no clear general desire benefit. AMD studies show some electrical-response improvements, but sustained visual benefit remains uncertain.

Help us improve this article

Spotted an error or found a source we should consider? Tell us which part of this article needs another look and include a link if you have one. Please leave out personal health details and lab results; we can’t answer individual medical questions.

Your name

Email address

What would you like to share?Select a topicCorrectionSource or research suggestionArticle requestAccessibility issueBusiness inquirySomething else

Your message

Continue to email →Email us directly